Results 71 to 80 of about 289,605 (341)

THE ROLE OF TUMOR-INFILTRATING LYMPHOCYTES IN TRIPLE NEGATIVE BREAST CANCER [PDF]

Romanian Journal of Medical Practice, 2018
Triple-negative breast cancer (TNBC), which lacks the expression of hormone receptors and human epidermal growth factor receptor-2 (HER2) represents the breast cancer subtype with the poorest prognosis.
Anca Zgura, Simona Carniciu, Laurentia Gales, Rodica Anghel   +3 more
doaj   +1 more source

Strength through diversity: how cancers thrive when clones cooperate

Molecular Oncology, EarlyView.
Intratumor heterogeneity can offer direct benefits to the tumor through cooperation between different clones. In this review, Kuiken et al. discuss existing evidence for clonal cooperativity to identify overarching principles, and highlight how novel technological developments could address remaining open questions.
Marije C. Kuiken, Maartje Witsen, Emile E. Voest, Krijn K. Dijkstra   +3 more
wiley   +1 more source

Progress and Prospect of Immunotherapy for Triple-Negative Breast Cancer

Frontiers in Oncology, 2022
Breast cancer is the most commonly diagnosed cancer (estimated 2.3 million new cases in 2020) and the leading cause of cancer death (estimated 685,000 deaths in 2020) in women globally.
C. Luo, Peipei Wang, Siqi He, Jing-Wei Zhu, Yuanyuan Shi, Jianxun Wang   +5 more
semanticscholar   +1 more source

Monitoring of circulating tumor DNA allows early detection of disease relapse in patients with operable breast cancer

Molecular Oncology, EarlyView.
Monitoring circulating tumor DNA (ctDNA) in patients with operable breast cancer can reveal disease relapse earlier than radiology in a subset of patients. The failure to detect ctDNA in some patients with recurrent disease suggests that ctDNA could serve as a supplement to other monitoring approaches.
Kristin Løge Aanestad, Marie Austdal, Oddmund Nordgård, Gunnar Mellgren, Satu Oltedal, Marie L. Austbø, Ylva H. Vignes, Thomas Helland, Kristin Jonsdottir, Tone H. Lende, Emilius A. M. Janssen, Bjørnar Gilje, Kjersti Tjensvoll, PBCB study group, Gunnar Mellgren, Tone Hoel Lende, Anette Heie, Kristin Viste, Anita Røyneberg Alvheim, Emiel AM Janssen, Kristin Jonsdottir, Ann Cathrine Kroksveen, Thomas Helland, Einar Gudlaugsson, Oddmund Nordgård, Satu Oltedal, Kristin Løge Aanestad, Jan Terje Kvaløy, Kirsten Lode, Kari Britt Hagen, Marie Austdal, Ylva H. Vignes, Siri Tungland Sola, Nina Egeland Amundsen, Finn Magnus Eliassen, Emeritus Ernst A Lien   +35 more
wiley   +1 more source

PI3K/AKT/mTOR signaling pathway: an important driver and therapeutic target in triple-negative breast cancer

Breast Cancer
Triple-negative breast cancer (TNBC) is a highly heterogeneous tumor lacking estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) expression.
Huan-ping Zhang, Rui-yuan Jiang, Jia-yu Zhu, Ke-na Sun, Yuan Huang, Huan-huan Zhou, Yabing Zheng, Xiao-jia Wang   +7 more
semanticscholar   +1 more source

African Ancestry–Associated Gene Expression Profiles in Triple-Negative Breast Cancer Underlie Altered Tumor Biology and Clinical Outcome in Women of African Descent

Cancer Discovery, 2022
Gene expression profiles in patients of African ancestry with triple-negative breast cancer indicate differences in normal breast tissue as well as in the tumor-associated immunologic profiles, supporting the potential differences in clinical outcomes ...
R. Martini, P. Delpe, T. Chu, K. Arora, Brittany Lord, A. Verma, Deepa Bedi, Balasubramanyam Karanam, Isra Elhussin, Yalei Chen, E. Gebregzabher, J. Oppong, Ernest K. Adjei, Aisha Jibril Suleiman, B. Awuah, M. Muleta, E. Abebe, I. Kyei, F. Aitpillah, M. Adinku, K. Ankomah, E. Osei-Bonsu, D. Chitale, J. Bensenhaver, D. Nathanson, L. Jackson, L. Petersen, E. Proctor, Brian Stonaker, K. Gyan, L. Gibbs, Zarko Manojlovic, R. Kittles, Jason A White, Clayton C Yates, U. Manne, K. Gardner, N. Mongan, E. Cheng, P. Ginter, S. Hoda, O. Elemento, N. Robine, A. Sboner, J. Carpten, Lisa Newman, M. Davis   +46 more
semanticscholar   +1 more source

LINC01116, a hypoxia‐lncRNA marker of pathological lymphangiogenesis and poor prognosis in lung adenocarcinoma

Molecular Oncology, EarlyView.
The LINC01116 long noncoding RNA is induced by hypoxia and associated with poor prognosis and high recurrence rates in two cohorts of lung adenocarcinoma patients. Here, we demonstrate that besides its expression in cancer cells, LINC01116 is markedly expressed in lymphatic endothelial cells of the tumor stroma in which it participates in hypoxia ...
Marine Gautier‐Isola, Rafael Lopes Goncalves, Marin Truchi, Caroline Lacoux, Célia Scribe, Hugo Cadis, Laetitia Guardini, Sophie Bekisz, Marius Ilié, Paul Hofman, Georges Vassaux, Bernard Mari, Roger Rezzonico   +12 more
wiley   +1 more source

Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: cohort A of the phase II KEYNOTE-086 study

Annals of Oncology, 2019
BACKGROUND Treatment options for previously treated metastatic triple-negative breast cancer (mTNBC) are limited. In cohort A of the phase II KEYNOTE-086 study, we evaluated pembrolizumab as second or later line of treatment for patients with mTNBC ...
S. Adams, P. Schmid, H. Rugo, Eric P. Winer, D. Loirat, A. Awada, D. Cescon, H. Iwata, M. Campone, R. Nanda, R. Hui, G. Curigliano, G. Curigliano, D. Toppmeyer, J. O’Shaughnessy, J. O’Shaughnessy, S. Loi, S. Paluch-Shimon, A. Tan, D. Card, J. Zhao, V. Karantza, J. Cortés   +22 more
semanticscholar   +1 more source

Characteristics of triple-negative breast cancer [PDF]

Journal of Cancer Research and Clinical Oncology, 2010
Triple-negative breast cancers (TNBC) neither express hormone receptors, nor overexpress HER2. They are associated with poor prognosis, as defined by low five-year survival and high recurrence rates after adjuvant therapy. Overall, TNBC share striking similarities with basal-like breast cancers (BBC), so a number of studies considered them being the ...
de Ruijter, Tim C., Veeck, Jurgen, de Hoon, Joep P. J., van Engeland, Manon, Tjan-Heijnen, Vivianne C.   +4 more
openaire   +3 more sources

Cell surface interactome analysis identifies TSPAN4 as a negative regulator of PD‐L1 in melanoma

Molecular Oncology, EarlyView.
Using cell surface proximity biotinylation, we identified tetraspanin TSPAN4 within the PD‐L1 interactome of melanoma cells. TSPAN4 negatively regulates PD‐L1 expression and lateral mobility by limiting its interaction with CMTM6 and promoting PD‐L1 degradation.
Guus A. Franken, Andrea Abel Gutierrez, Imke van Rossum, Cornelia G. Spruijt, Michiel Vermeulen, Guido van Mierlo, Blanca Scheijen, Annemiek B. van Spriel   +7 more
wiley   +1 more source